BROWSERSTACK
BrowserStack , the world's leading software testing platform, today announced the acquisition of Nightwatch.js, the popular open-source test automation framework. BrowserStack will work with the Nightwatch team to make Nighwatch.js the de-facto choice for developers. Nightwatch.js will continue to remain open-source and free.
Nightwatch.js, the Node.js powered end-to-end test automation framework, is among the fastest-growing Selenium-based tools with 1 million monthly npm installs and over 10.5k GitHub stars. With its simple syntax and an in-built test runner, developers can run and manage tests without any hassle.
“Partnering with BrowserStack gives us the resources to build for the future and scale Nightwatch to greater heights,” said Andrei Rusu, Creator of Nighwatch.js. “Our focus will be to proactively engage with the community for feedback and roll out updates to improve the core experience for developers. We've already launched Nightwatch 2.0 in beta, and we're excited about the next chapter.”
Welcoming Nightwatch.js into its family of open-source collaborations, BrowserStack is doubling down on its support for the community and intends to scale such partnerships in the future. BrowserStack's Open Source Team actively participates and contributes to the open-source ecosystem. In addition, through its Open Source Program, BrowserStack has backed over 2,400 open source projects, enabling maintainers and contributors to test their software for free.
“When open-source wins, everyone wins. Many of BrowserStack's own products are built on open-source technologies, and we know first-hand their power to bring significant change,” said Nakul Aggarwal, Co-founder and CTO of BrowserStack. “With Nightwatch.js, we're taking another step towards our vision of becoming the testing infrastructure for the internet—through open and inclusive development.”
About BrowserStack
BrowserStack is the world's leading software testing platform powering over two million tests every day across 15 global data centers. They help Microsoft, Twitter, Barclays, Expedia, and over 50,000 customers deliver quality software at speed by moving testing to our Cloud. Their platform provides instant access to 2,500+ real mobile devices and browsers on a highly reliable cloud infrastructure that effortlessly scales as testing needs grow. With BrowserStack, Dev and QA teams can move fast while delivering an amazing experience for every customer.
Founded in 2011, BrowserStack is a privately held company backed by Accel with offices in San Francisco, Mumbai, and Dublin. For more information, visit https://www.browserstack.com or follow on Twitter @browserstack .
About Nightwatch.js
Nightwatch.js is an integrated, open-source end-to-end testing solution for web applications and websites written in Node.js. Released in 2014, their vision is to deliver a tool packed with everything developers need out of the box to ship bug-free software easily. For more details, visit https://nightwatchjs.org/ or follow on Twitter @nightwatchjs .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005737/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Original “Titanic Cherub” From James Cameron’s Epic Film Heads to Auction December 9 & 1024.11.2025 21:48:00 CET | Press release
Iconic Hollywood Artifact Indelibly Linked with “Jack & Rose” Portrayed by Kate Winslet and Leonardo DiCaprio One of the most recognizable and beloved set pieces from James Cameron’s Titanic heads to auction on December 9 &10 —the original Grand Staircase Cherub, seen in multiple scenes of the 1997 blockbuster, including the pivotal moment when Jack and Rose meet in front of the First Class Dining Room and the climactic moment when the Atlantic Ocean bursts through the skylight and floods the staircase, and cherub. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124056883/en/ The iconic “cherub” with Leonardo DiCaprio & Kate Winslet in James Cameron’s “TITANIC”. The ornate fixture—crafted for the full-scale recreation of Titanic’s Grand Staircase—was gifted by the production to Martin Biallas, CEO of SEE Global Entertainment, whose immersive exhibitions have brought the world’s most famous ship to millions of fans. It now
Access Advance Announces Major Growth in Its HEVC and VVC Patent Pools24.11.2025 16:10:00 CET | Press release
Access Advance LLC today announced significant expansions of both its HEVC Advance and VVC Advance Patent Pools during the second and third quarters of 2025, underscoring continued industry confidence in the company's balanced and transparent approach to video codec licensing. This growth follows the successful January 2025 launch of Access Advance's Video Distribution Patent ("VDP") Pool, demonstrating the company's expanding role in comprehensive video codec patent licensing solutions. Among the many highlights, Sharp Corporation joined the HEVC Advance Patent Pool as a Licensor, bringing valuable intellectual property assets to the pool's already extensive patent portfolio. Additionally, Huawei Technologies Co., Ltd., already an HEVC Advance Licensor and Licensee, expanded its collaboration with Access Advance by joining the VVC Advance Patent Pool as a Licensee. HP Inc. also expanded its license to include the VVC Advance Patent Pool after previously joining HEVC Advance in 2024, w
Microsize and Schedio Group to Acquire Lonza’s Micro-Macinazione Site in Switzerland24.11.2025 15:05:00 CET | Press release
Microsize, a leading CDMO specializing in particle size reduction and control technologies, today announced it has signed an agreement to acquire Micro-Macinazione (Mic Mac), a dedicated micronization facility in Monteggio, Switzerland, from Lonza. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124545344/en/ The agreement represents Microsize’s second acquisition from Lonza, following the successful 2022 divestment of its Quakertown, Pennsylvania site. In this transaction, Schedio Group – a Swiss-based provider of jet mills, isolators, spray dryers, and engineering services – is investing alongside Microsize to strengthen and localize its operational base in Europe, advancing a shared vision to lead the next generation of integrated particle engineering solutions. With more than 30 years of experience, Mic Mac has served the pharmaceutical industry with proven GMP-compliant jet milling and micronization capabilities for b
Hytera to Debut S1 E at PMRExpo 202524.11.2025 14:17:00 CET | Press release
Hytera, a leading global provider of critical communications technologies and solutions, today introduced the S1 E, a business-ready, palm-sized two-way radio designed specifically for the retail sector, expanding the portfolio of S Series and providing one more option for retail users to choose for their daily operations. The S1 E will make its debut at PMRExpo, the Europe's premier trade fair for secure, mission- and business-critical communication, taking place from November 25th to 27th, 2025, at Koelnmesse in Cologne, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251124768341/en/ Hytera New Released Licence-free Analogue Business Radio S1 E Adhering to the S Series’ signature design language, the S1 E combines a stylish, modern, and minimalist aesthetic with practical functionality. Weighing under 85g, the S1 E provides all-day wearing comfort without tugging or weighing down uniforms. Key enhancements and sta
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis24.11.2025 14:00:00 CET | Press release
Cladribine capsules have the potential to be the first oral treatment for people living with rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia GravisCladribine capsules has received Fast Track designation and Orphan Drug Designation by the US FDAMerck has established an MG patient council to provide insights on how to best meet the needs of patients in the gMG rare disease community Merck, a leading science and technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for cladribine capsules for the treatment of the rare, chronic autoimmune neuromuscular disorder, generalized Myasthenia Gravis (gMG). In June 2023, the FDA granted Orphan Drug Designation for cladribine capsules for the treatment of gMG. In addition, the Company is actively collaborating with patient organizations and Ad Scientiam, a medical technology company, to support a patient-directed approach to the future management of gMG. If approved
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom